LIFE - aTyr Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.28
+0.05 (+1.00%)
As of 12:22PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close5.23
Open5.26
Bid5.25 x 1100
Ask5.29 x 3200
Day's Range5.20 - 5.46
52 Week Range4.08 - 12.88
Volume79,495
Avg. Volume65,900
Market Cap18.638M
Beta (3Y Monthly)2.02
PE Ratio (TTM)N/A
EPS (TTM)-13.56
Earnings DateAug 13, 2018 - Aug 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    aTyr Pharma to Host Key Opinion Leader Call and Webcast on Sarcoidosis and the Current Treatment Landscape

    SAN DIEGO, July 10, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will host a Key Opinion Leader (KOL) call and webcast on pulmonary sarcoidosis and the current treatment landscape on Thursday, July 18th at 2pm Eastern Time/11am Pacific Time. The call will feature a presentation by KOL Daniel Culver, DO, from the Cleveland Clinic, who will discuss the current standard of care and unmet medical need in treating patients with pulmonary sarcoidosis.

  • GlobeNewswire16 days ago

    aTyr Pharma Strengthens Board of Directors with the Appointment of Two New Members

    SAN DIEGO, July 01, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointments of Jane Gross, Ph.D. and Svetlana Lucas, Ph.D. to the Company’s Board of Directors. “As we continue to advance ATYR1923 through clinical development in pulmonary sarcoidosis and further expand our pipeline of  therapeutic candidates, we believe their respective skill sets in research and development and business development are ideally suited to help guide us through our next phase of growth. Dr. Jane Gross is an accomplished executive with more than 28 years of experience leading research and development in the design and development of therapeutics for the treatment of autoimmune, inflammatory diseases and cancer.  Dr. Gross has deep experience in research and development, partnering and alliance management of multiple internal and co-development programs.

  • GlobeNewswire19 days ago

    aTyr Pharma Announces Reverse Stock Split to Regain NASDAQ Compliance

    SAN DIEGO, June 28, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its Board of Directors has approved a one-for-14 reverse stock split of its common stock that is scheduled to become effective after trading closes on June 28, 2019. The company’s common stock will begin trading on the Nasdaq Capital Market on a split adjusted basis when the market opens on July 1, 2019. The company’s common stock will continue to trade under the symbol “LIFE.” At the company’s Annual Meeting of Stockholders held on May 8, 2019, the company’s stockholders approved a proposal authorizing the company’s Board of Directors to effect a reverse stock split in a range of 1:3 to 1:15 to help regain compliance with the Nasdaq minimum bid price requirement.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of LIFE earnings conference call or presentation 13-May-19 9:00pm GMT

    Q1 2019 aTyr Pharma Inc Earnings Call

  • Associated Press2 months ago

    Atyr Pharma: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 18 cents. In the final minutes of trading on Monday, the company's shares hit 53 cents. A year ago, they were trading at $2.30. _____ ...

  • GlobeNewswire2 months ago

    aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update

    Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients ongoing Advanced lead position in Neuropilin-2 (NRP-2) biology with inaugural NRP-2.

  • GlobeNewswire2 months ago

    aTyr Pharma to Announce First Quarter 2019 Results on May 13th

    SAN DIEGO, May 06, 2019 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.

  • GlobeNewswire3 months ago

    aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology

    SAN DIEGO, April 16, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the Company will host a summit meeting on Neuropilin-2 (NRP-2) biology on April 17, 2019 in San Diego. This one-day summit meeting will bring together key researchers from across the United States to discuss the most recent discoveries relating to the development of therapeutics directed to the NRP-2 co-receptor, and related signaling pathways. “We are pleased to host this inaugural summit meeting which should serve to advance our collective understanding of the emerging role of NRP-2 in modulating immune responses across a broad range of disease states,” said Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr.

  • GlobeNewswire3 months ago

    aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund

    SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a definitive agreement with The Federated Kaufmann Small Cap Fund and Paul Schimmel, Ph.D., an existing stockholder and a director of the company, to purchase an aggregate of $5.0 million of aTyr’s common stock in a registered direct offering conducted without an underwriter or placement agent. Proceeds from the offering will be used to advance clinical development of aTyr’s lead therapeutic candidate, ATYR1923, and for other general corporate purposes. The securities described above are being offered pursuant to a shelf registration statement (File No. 333-211998) filed with the Securities and Exchange Commission (SEC), which was declared effective on June 22, 2016.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of LIFE earnings conference call or presentation 25-Mar-19 9:00pm GMT

    Q4 2018 aTyr Pharma Inc Earnings Call

  • GlobeNewswire3 months ago

    aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference

    SAN DIEGO, April 08, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the Company will present an abstract in a poster presentation at the American Thoracic Society (ATS) 2019 International Conference, which is being held May 19-22 in Dallas. ”We are very pleased to present these compelling results at this year’s ATS conference, which highlight ATYR1923’s unique mechanism of action and demonstrate activity in a range of ILD models,” said Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr. “Notably, ATYR1923 appears to show potent immunomodulatory effects in models of fibrosing ILD that are highly inflammatory or T cell driven.

  • Atyr Pharma (LIFE) Upgraded to Buy: Here's Why
    Zacks4 months ago

    Atyr Pharma (LIFE) Upgraded to Buy: Here's Why

    Atyr Pharma (LIFE) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Associated Press4 months ago

    Atyr Pharma: 4Q Earnings Snapshot

    The San Diego-based company said it had a loss of 21 cents per share. For the year, the company reported that its loss narrowed to $34.5 million, or $1.15 per share. In the final minutes of trading on ...

  • GlobeNewswire4 months ago

    aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update

    Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients initiated in December 2018 First tRNA synthetase partnership announced in March.

  • ACCESSWIRE4 months ago

    aTyr Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 25, 2019 / aTyr Pharma, Inc. (NASDAQ: LIFE ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 25, 2019 at 5:00 PM Eastern ...

  • GlobeNewswire4 months ago

    aTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting

    SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that data from its successful pilot study with the University of Nebraska Medical Center will be presented in an abstract at the 2019 AACR Annual Meeting, which is being held March 29 - April 3 at the Georgia World Conference Center in Atlanta. The poster may be accessed on the aTyr Pharma website at https://www.atyrpharma.com/our-science/publications/ following the presentation.

  • GlobeNewswire4 months ago

    aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th

    SAN DIEGO, March 18, 2019 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.

  • GlobeNewswire4 months ago

    aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring

    SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a research collaboration and option agreement with global biotherapeutics leader CSL Behring, for the development of product candidates derived from up to four tRNA synthetases from aTyr’s preclinical pipeline. “This research collaboration with CSL Behring, an industry leader in the development of plasma-derived and recombinant therapeutics for rare and serious diseases, represents an important validation of our science and enables us to accelerate development of potential IND candidates from our pipeline,” said Dr. Sanjay Shukla, President and Chief Executive Officer of aTyr.

  • GlobeNewswire4 months ago

    aTyr Pharma Announces Participation at March Investor Conferences

    SAN DIEGO, March 04, 2019 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.

  • GlobeNewswire5 months ago

    aTyr Pharma Presents Compelling Preclinical Data Highlighting Potential of ATYR1923 to Regulate Myeloid Cell Biology During Lung Inflammation

    SAN DIEGO, Feb. 27, 2019 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.

  • CNW Group5 months ago

    Evolve Announces February 2019 Distributions for Evolve ETFs

    Evolve Announces February 2019 Distributions for Evolve ETFs

  • GlobeNewswire5 months ago

    aTyr Pharma to Present at the BIO CEO & Investor Conference

    SAN DIEGO, Feb. 05, 2019 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.

  • GlobeNewswire6 months ago

    aTyr Pharma Announces Research Collaboration with the University of Nebraska Medical Center and Expansion of Successful Pilot Study

    Collaboration to advance neuropilin-2 biology and explore potential therapeutic opportunities for ATYR1923 Reinforces aTyr’s commitment to working with a strategic network of.

  • GlobeNewswire6 months ago

    Pangu BioPharma (an aTyr Pharma Subsidiary) and The Hong Kong University of Science and Technology Recognized for Pioneering Work Leading to New Investigational Therapeutic for Lung Disease

    SAN DIEGO and HONG KONG, Jan. 16, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today recognized the collaboration between its Hong Kong subsidiary, Pangu BioPharma (Pangu), and The Hong Kong University of Science and Technology (HKUST) for contributions leading to the discovery of aTyr’s lead clinical candidate, ATYR1923, which is currently being evaluated in a Phase 1b/2a study in patients with pulmonary sarcoidosis.

  • Zacks.com featured highlights include: G-III, SP Plus, Penske Automotive, aTyr and Avinger
    Zacks6 months ago

    Zacks.com featured highlights include: G-III, SP Plus, Penske Automotive, aTyr and Avinger

    Zacks.com featured highlights include: G-III, SP Plus, Penske Automotive, aTyr and Avinger